Fabio Efficace
Overview
Explore the profile of Fabio Efficace including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
255
Citations
3628
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Li J, Davidson P, Fong D, Li Y, Lok K, Wong J, et al.
J Glob Health
. 2025 Feb;
15:04091.
PMID: 39950570
Background: Given the limited understanding of individuals' positive gains, this study aimed to identify these gains that could be leveraged by policymakers to enhance future health and societal resilience. Methods:...
2.
Venditti A, Palmieri R, Maurillo L, Rollig C, Wierzbowska A, De Leeuw D, et al.
Blood Adv
. 2025 Feb;
PMID: 39913928
Fitness assessment in patients with acute myeloid leukemia (AML) is critical to deliver the right therapy to the right patient. While several scoring systems are available to aid in determining...
3.
Blackstone E, Efficace F, Meyerhardt J, Abel G
J Clin Oncol
. 2025 Jan;
JCO2402021.
PMID: 39836934
No abstract available.
4.
Li J, Fong D, Lok K, Wong J, Man Ho M, Choi E, et al.
J Glob Health
. 2025 Jan;
15():04011.
PMID: 39791329
Background: We aimed to identify the central lifestyle, the most impactful among lifestyle factor clusters; the central health outcome, the most impactful among health outcome clusters; and the bridge lifestyle,...
5.
Al-Naesan I, Krepper D, Sparano F, Sztankay M, Efficace F, Giesinger J
Melanoma Res
. 2024 Dec;
35(2):77-86.
PMID: 39668671
The objective of this study was to provide an overview of the current practice of patient-reported outcome (PRO) assessments in trials investigating treatment with BRAF inhibitors in patients with advanced...
6.
Shah D, Sparano F, Luo C, Krepper D, Giesinger J, Baldi T, et al.
Ann Hematol
. 2024 Dec;
103(12):5849-5859.
PMID: 39644334
Patient-reported outcomes (PROs) are crucial endpoints in multiple myeloma (MM) randomized controlled trials (RCTs), yet there is significant variability in their methodology and reporting. Our study aimed to (a) identify...
7.
Osanto S, Vliert-Bout A, Gomez de Segura C, Efficace F, Sparano F, Willemse P, et al.
EClinicalMedicine
. 2024 Dec;
78:102914.
PMID: 39619239
Background: Since 2015 multiple combination treatments became available for metastatic hormone-sensitive prostate cancer (mHSPC) without effectiveness cross-comparison. Health-related quality of life (HRQoL) could aid in decision-making. Methods: We systematically reviewed...
8.
Tadesse F, Sparano F, Gebremedhin A, Abubeker A, Piciocchi A, Cipriani M, et al.
JCO Glob Oncol
. 2024 Nov;
10:e2400281.
PMID: 39541560
Purpose: Health-related quality of life (HRQoL) is now an important goal of therapy for patients with chronic myeloid leukemia (CML). However, there is paucity of data for patients living in...
9.
Efficace F, Sparano F, Breccia M, Greco C, Carluccio P, Borlenghi E, et al.
Ann Hematol
. 2024 Oct;
103(12):5341-5349.
PMID: 39438322
Very limited evidence is available on the long-term health-related quality of life (HRQoL) of patients with acute promyelocytic leukemia (APL) treated with arsenic trioxide (ATO). We performed an extended follow-up...
10.
Komrokji R, Lanino L, Ball S, Bewersdorf J, Marchetti M, Maggioni G, et al.
Lancet Haematol
. 2024 Oct;
11(11):e862-e872.
PMID: 39393368
The WHO and International Consensus Classification 2022 classifications of myelodysplastic syndromes enhance diagnostic precision and refine decision-making processes in these diseases. However, some discrepancies still exist and potentially cause inconsistency...